Clinical trials: Urinary
Bladder Cancer
Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus…
- Trial name
- NCT00461591
- Testing
- Apaziquone, TURBT
- Where
- 74 sites in United States
- Volunteers
- 802 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Urinary Tract Infection Symptomatic, Acute Pyelonephritis
Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections
The purpose of the study is to demonstrate the safety and efficacy of ZTI-01 (IV fosfomycin) as non-inferior to piperacillin/tazobactam in overall success (clinical cure and microbiologic eradication) for the treatment of…
- Conditions
- Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
- Trial name
- ZEUS (NCT02753946)
- Testing
- ZTI-01, Piperacillin-tazobactam
- Where
- 68 sites in United States, Belarus and 14 more
- Volunteers
- 465 people
- Sponsor
- Nabriva Therapeutics AG
Cystitis, Interstitial, Painful Bladder Syndrome
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT02411110
- Testing
- LiRIS®
- Where
- 34 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Allergan
Interstitial Cystitis, Pelvic Pain
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects quality of life.
- Trial name
- NCT01731470
- Testing
- Liposomes
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Kenneth Peters, MD
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Overactive Bladder
Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial
This study will evaluate the cerebrospinal fluid levels of trospium chloride (Sanctura XR®) and oxybutynin immediate release (Oxybutynin IR) on memory performance in patients with overactive bladder and age associated memory…
- Trial name
- NCT01178827
- Testing
- trospium chloride, oxybutynin IR
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Allergan
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Bladder Cancer
Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors
This is a phase II, single center open label to determine safety, dose tolerance, PK and PD of the recommended Phase 2 dose (RP2D) of CPX-POM administered in patients with any newly diagnosed or recurrent bladder tumors.
- Trial name
- NCT04525131
- Testing
- CPX-POM
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- CicloMed LLC
Overactive Bladder With Urge Urinary Incontinence
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder…
- Trial name
- NCT04211831
- Testing
- URO-902
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Urovant Sciences GmbH
Urinary Tract Infection
Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)
This is a study of patients undergoing gynecologic surgery who require post-operative catheterization to determine if prophylactic antibiotic treatment decreases the risk of post-operative urinary tract infection in these…
- Trial name
- STOPP UTI (NCT01450800)
- Testing
- Nitrofurantoin
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Duke University
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Overactive Bladder
This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder
The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for…
- Trial name
- NCT00943735
- Testing
- Fesoterodine, Your Way
- Volunteers
- 774 people
- Sponsor
- Pfizer
Urinary Tract Infection
Cranberry for UTI Prevention in Residents of Long Term Care Facilities
Urinary tract infections (UTIs) affect over 7 million men and women per year and cost the health care industry over 1 billion dollars annually.
- Trial name
- PACS (NCT00596635)
- Testing
- Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Yale University
Urothelial Cancer
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy.
- Trial name
- NCT02335424
- Testing
- pembrolizumab
- Volunteers
- 374 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder Symptoms
The purpose of this study is to determine if long acting tolterodine confers more benefit than intravaginal low dose estrogen in the treatment of Overactive Bladder Syndrome at 12 weeks post-treatment initiation.
- Trial name
- DRIVE (NCT00465894)
- Testing
- Extended Release Tolterodine LA, Intra Vaginal Estradiol Cream
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Overactive Bladder
Procedural Discomfort Related to Number of Intradetrusor Botox Injections
Injection of intradetrusor OnabotulinumtoxinA (BTX-A) is a highly efficacious therapy with a reliable safety profile and demonstrable improvements in subjective and objective measures for overactive bladder (OAB) symptom control.
- Trial name
- BIND (NCT05652036)
- Testing
- Intradetrusor Botox Injections
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- The Methodist Hospital Research Institute
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Spinal Cord Injury, Neurogenic Bladder
The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury
The purpose of this research study is to evaluate the effects upon the bladder of electric stimulation of the leg's tibial nerve in people with acute spinal cord injury with an intervention called transcutaneous tibial nerve…
- Trial name
- NCT02573402
- Testing
- Transcutaneous Tibial Nerve Stimulation, Control
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center, Houston
Urinary Tract Infections
Cranberry Effect on Urinary Tract Infections
This is a retrospective chart review using Electronic Privacy Identification Center (EPIC) database to determine if the addition of cranberry juice capsules to our discharge medication regimen for patients discharged home with an…
- Trial name
- NCT02996981
- Volunteers
- 167 people
- Sponsor
- TriHealth Inc.
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and…
- Trial name
- Dolphin (NCT04641975)
- Testing
- Mirabegron
- Where
- 15 sites in Belgium, France and 8 more
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Global Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.